1Jeyabalan A, Shroff SG, Novak J, et al. The vascular actions of relaxin[J]. Adv Exp Med Biol, 2007, 612: 65-87.
2Conrad KP, Debrah DO, Novak J, et al. Relaxin modifies systemic arterial resistance and compliance in conscious, non- pregnant rats [J]. Endocrinology, 2004,145(7): 3289-3296.
3Fisher C, MacLean M, Morecroft I, et al. Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart? [J]. Circulation, 2002 , 106(3) :292-295.
4Dschietzig T, Teichman SL, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability and pharmacodynamic trial[J]. J Card Fail,2009 ,15(3) :182- 190.
5Danielson LA, Kercher LJ, Conrad KP. Impact of gender and endothelin on renal vasodilation and hyperfiltration induced by relaxin in conscious rats[J]. Am J Physiol Regul Integr Comp Physiol, 2000, 279(4), R1298-R1304.
6Dschietzig T, Bartsch C, Richter C et al. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: at- tenuation of endothelin-1 mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear faetor-kappaB[J]. Circ Res, 2003, 92 (1) : 32-40.
7Massicotte G, Parent A, St Louis J. Blunted responses to vasoconstrictors in mesenterie vasculature but not in portal vein of spontaneously hypertensive rats treated with relaxin[J]. Proc Soc Exp Biol Med, 1989,190(3): 254-259.
8Novak J, Ramirez RJ, Gandley RE,et al. Myogenic reactivi ty is reduced in small renal arteries isolated from relaxin-trea- ted rats[J].Am J Physiol Regul lntegr Comp Physiol, 2002, 283(2) :R349 -R355.
9Danielson LA, Sherwood OD, Conrad KP, Relaxin is a po tent renal vasodilator in conscious rats [J]. J Clin Invest, 1999,103(4) :525-533.
10Bani-Sacchi T, Bigazzi M, Bani D, et al. Relaxin-induced increased coronary flow through stimulation of nitric oxide production[J]. Br J Pharmacol, 1995,116(1) :1589-1594.
3Papp Z,Csapo K,Pollesello P. Pharmacological mechanismscontributing to the clinical efficacy of levosimendan[J].Cardiov Dsc Drug Rev,2005,(01):71.
4Kangawa K,Matsuo H. Purification and complete amino acid sequence of alphahuman atrial natriuretic polypeptide (alpha-hANP)[J].Biochemical and Biophysical Research Communications,1984,(01):131-139.
5SUN Y, Weber KT. Infarct scar: a dynamic tissue. [J] Cardiovasc Res, 2000,46(2) :250-256.
6Tamarappoo BK, John BT, Reinier K, et aI. Vulnerable myocardial interstitium in patients with isolated left ventricular hypertrophy and sudden cardiac death: a postmortem histological evaluation[J]. Am Heart Assoc. 2012,1 (3) : e001511.
7Jiang B, Dong H, Li Q, et al. Differentiation of reprogranuned mouse cardiac fibroblasts into functional cardiomyocytes[J]. Cell Biochem Biophys, 2013 ,66(2) : 309-318.
8Thum T, Gross C, Fiedler J ,et aI. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts[J]. Nature,2008, 456 (7224): 98(}-984.
9Banypersad SM, Moon JC, Whelan C, et al. Updates in cardiac amyloidosis: a review[J]. Am Heart Assoc, 2012, 1 (2) : e000364.
10Wong TC, Piehler KM, Kang lA, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission[J]. Eur Heart, 2014,35(10): 657-664.
